Incyte(NASDAQ) INCY

Incyte makes medicines for blood cancers and skin disorders. Its products help people manage immune system and tumor issues. These therapies target patients with few other medical options.

Medicines for Rare Conditions

• Hematology Franchise: Treatments for rare blood cancers and immune responses; includes JAKAFI for myelofibrosis and graft-versus-host disease.
• Dermatology Portfolio: Topical creams for chronic skin inflammation and pigment loss; features OPZELURA for atopic dermatitis and vitiligo.
• Oncology Assets: Targeted drugs for rare solid and liquid tumors; includes treatments for biliary tract and Merkel cell cancers.

Strategy for Global Growth

• Acquired Vega Therapeutics in July 2026 for $1.25 billion to add a Phase 3 candidate for blood disorders.
• Launched JAKAFI XR in May 2026 following federal regulatory approval for multiple indications.
• Purchased exclusive global rights for the antibody therapy tafasitamab in February 2024.
• Licensed an investigational bone disorder drug to Mirum Pharmaceuticals in April 2026.

Innovation Beyond the Lab

The company maintains central operations in Delaware while expanding into international markets. Its research focus covers rare blood cancers, solid tumors, and autoimmune skin diseases.

By the Numbers

• Total revenues reached $2.9 billion for the six months ended June 30, 2026.
• Net income rose to $888.9 million during the six months ended June 30, 2026.
• JAKAFI net sales were $1.6 billion for the six-month period ended June 30, 2026.
• OPZELURA net sales reached $592.8 million for the first half of 2026, including a $246.0 million litigation benefit.
• Market capitalization was $22.7 billion in the second quarter of 2026.

Bottom Line

Incyte has evolved from a research firm into a commercial biopharmaceutical leader with multiple approved products. Its focus on rare diseases and dermatology continues to support its global expansion.